Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | PAK4 | O96013 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367344 | 0.85 | GRK5 (0.51) | GSK3BJAK3PAK4KDREGFR | |
| SCHEMBL5366782 | 0.82 | PDPK1 (0.60) | TLK2JAK3KDRMAPT | |
| SCHEMBL5366834 | 0.81 | GSK3B (0.52) | GSK3BTLK2JAK3PAK4KDR | |
| SCHEMBL5361474 | 0.81 | TLK2 (0.70) | TLK2JAK3PAK4KDREGFR | |
| SCHEMBL13712838 | 0.81 | GSK3B (0.55) | GSK3BTLK2JAK3KDREGFR | |
| SCHEMBL5364206 | 0.80 | JAK3 (0.47) | TLK2JAK3PAK4KDRMAPT | |
| SCHEMBL5361229 | 0.79 | AKT2 (0.59) | GSK3B | |
| SCHEMBL5359359 | 0.79 | TLK2 (0.47) | TLK2JAK3KDRRETMAPT | |
| SCHEMBL5362148 | 0.78 | KDR (0.48) | GSK3BTLK2JAK3KDRPDGFRB | |
| SCHEMBL5363197 | 0.77 | TLK2 (0.80) | TLK2JAK3PAK4PDGFRBNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | GSK3B 315/4885TLK2 48/4885JAK3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.